Abstract 45P
Background
Although 4 molecular subtypes of endometrial cancer (EC) by The Cancer Genome Atlas (TGGA) have distinctive prognostic features, prognosis within each subtype could vary depending on histological and molecular factors. By merging omics datasets and machine learning analyses, we attempted to identify biomarkers related to the recurrence within each molecular subtype.
Methods
From TCGA multi-omics datasets, 116 EC samples with DNA methylation, RNA-seq, and common variants as well as recurrence data were used for analysis. Differentially expressed genes (DEGs) and differentially methylated regions (DMRs) were retrieved by t-test between the recurrence and non-recurrence groups. DEGs and DMRs were visualized using volcano plots and heat maps. The machine learning approaches, namely decision tree (DT) and random forest (RF) models, were used to find the molecular factors to best discriminate the following 4 groups: copy number-high (CN-H) with recurrence, CN-H without recurrence, copy number-low (CN-L) with recurrence, and CN-L without recurrence. Critical gene expressions or DNA methylation levels in each molecular subtypes were presented as a boxplot.
Results
Three omics datasets were merged with 378,278 CpG sites, 53,409 normalized gene expression levels, 118,555 genomic region variants, and 18,603 gene variants. Through DT and RF, PARD6G-AS1, CSMD1, TESC, and CD44 were selected. Boxplot revealed that hypomethylation of PARD6G-AS1, hypermethylation of CSMD1, and increased TESC expression were significantly associated with increased risk of recurrence in the CN-H group. Also, overexpression of CD44 was significantly associated with recurrence in the CN-L group. After validation of these 4 parameters using TCGA raw data, PARD6G-AS1 and CD44 remained their statistical significance (P=0.006 and 0.020, respectively). Hypomethylation of PARD6G-AS1 in CN-H and CD44 overexpression in CN-L demonstrated significant association with both advanced stage and lymph node metastasis.
Conclusions
Hypomethylation of PARD6G-AS1 in CN-H and CD44 overexpression in CN-L could be predictive markers in endometrial cancer recurrence.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract